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DOI 10.1016/j.ccr.2012.04.024SUMMARYStromal responses elicited by early stage neoplastic lesions can promote tumor growth. However, themolec-
ularmechanisms that underlie the early recruitment of stromal cells to sites of neoplasia remain poorly under-
stood. Here, we demonstrate an oncogenic KrasG12D-dependent upregulation of GM-CSF in mouse pancre-
atic ductal epithelial cells (PDECs). An enhanced GM-CSF production is also observed in human PanIN
lesions. KrasG12D-dependent production of GM-CSF in vivo is required for the recruitment of Gr1+CD11b+
myeloid cells. The suppression of GM-CSF production inhibits the in vivo growth of KrasG12D-PDECs, and,
consistent with the role of GM-CSF in Gr1+CD11b+mobilization, this effect ismediated byCD8+ T cells. These
results identify a pathway that links oncogenic activation to the evasion of antitumor immunity.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive
malignancy with a dismal long-term prognosis. Indeed, the
disease exhibits a median survival of less than 6 months and
a 5-year survival rate of 3%–5% (Kern et al., 2011; Maitra and
Hruban, 2008). PDA evolves through a series of histopatholog-
ical changes, referred to as pancreatic intraepithelial neoplasia
(PanIN), accompanied by a recurrent pattern of genetic lesions,
the earliest and most ubiquitous of which is oncogenic activa-
tion of Kras (Hong et al., 2011; Maitra and Hruban, 2008;
Shi et al., 2008). The essential role of oncogenic Kras in the
pathogenesis of PDA is indicated by several genetically
engineered mouse models, wherein the conditional expression
of the mutated allele of Kras in the pancreas is necessary and/
or sufficient to drive disease progression from the early preinva-
sive to a malignant stage (Hingorani et al., 2003; Seidler et al.,
2008). Though the mechanisms by which oncogenic KrasSignificance
Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive
cancer-related deaths in the United States. PDA developm
responses and immune surveillance programs. However, th
been clearly defined. In this study, we demonstrate that muta
the production of GM-CSF, which, in turn, promotes the exp
leading to the evasion of CD8+ T cell-driven antitumor immun
antitumor immune response and provide insights into critical b
against pancreatic cancer.
836 Cancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc.contributes to the genesis and progression of PDA have not
been fully elucidated, the proliferative and survival advantages
conferred on epithelial cells by the expression of endogenous
oncogenic Kras have been clearly implicated (Pylayeva-Gupta
et al., 2011).
In addition to the well-documented molecular and histological
alterations exhibited by the tumor cells themselves, as well as
by their preneoplastic precursors, a hallmark of PDA is an exten-
sive stromal remodeling, the most prominent features of which
are the recruitment of inflammatory and mesenchymal cells as
well as fibrotic replacement of the pancreatic parenchyma
(Chu et al., 2007; Kleeff et al., 2007; Maitra and Hruban, 2008).
Strikingly, histological assessment of pancreata of human
patients afflicted with PDA or mice engineered to express onco-
genic Kras in the epithelial compartment of the pancreas reveals
that even early stages of PanIN development are associated with
a stromal reaction, which is characterized by a robust desmo-
plastic response and recruitment of immune cells (Chu et al.,malignancy currently ranked as the fourth-leading cause of
ent is accompanied by pronounced changes in stromal
e mechanisms that contribute to these changes have not
tional activation of Kras in pancreatic ductal cells triggers
ansion of immunosuppressive Gr1+CD11b+ myeloid cells,
ity. Our findings implicate oncogenic Kras in restraining the
arriers for designing effective immunotherapeutic strategies
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KrasG12D Modulates Immunity in Pancreatic Cancer2007; Clark et al., 2007). However, the precise role played by the
PanIN-associated stroma in PDA development has not been es-
tablished. On the basis of the composition of the immune
infiltrates surrounding the PanINs, it has been proposed that
the stromal constituents around PanINs form an inflammatory
and immune suppressive environment, thereby allowing the
precursor lesions to escape immune surveillance (Clark et al.,
2009). Consistent with this idea, studies in both humans and
mice have demonstrated a dampened adaptive immune
response accompanying the formation of oncogenic Ras-driven
cancers (Clark et al., 2009; DuPage et al., 2011; Fossum et al.,
1995; Gjertsen and Gaudernack, 1998; Kubuschok et al., 2006;
Qin et al., 1995; Weijzen et al., 1999). Moreover, there is growing
evidence that targeting the tumor immune microenvironment
may provide an effective therapeutic strategy (Quezada et al.,
2011).
To explore the functional interactions between PanINs and
their microenvironment, we sought to identify the mechanisms
by which precursor lesions harboring oncogenic Kras instigate
a stromal response.
RESULTS
To investigate the role of oncogenic Kras in modulating the host
immune response during PanIN evolution, we established an
orthotopic allograft system in which primary ductal epithelial
cells (PDECs) isolated from LSL-KrasG12D knock-in mice were
injected into the pancreata of syngeneic C57Bl/6 mice. The
expression of the KrasG12D allele in these cells was induced prior
to implantation by Cre-mediated recombination, as previously
described (Lee and Bar-Sagi, 2010); for the purpose of their
in situ identification, the cells were engineered to express green
fluorescent protein (GFP). Unless otherwise specified, these
cells are referred to throughout the article as GFP-KrasG12D-
PDECs. To minimize the possibility of a genetic drift, PDECs
were propagated in culture only for a limited number of passages
(<16). As illustrated in Figure 1A, implanted GFP-KrasG12D-
PDECs formed ductal structures of heterogeneous size and
architecture mostly resembling early PanIN lesions and reactive
ducts. Notably, the grafts were characterized by a pronounced
localized desmoplasia (Trichrome staining, Figure 1A) and the
overt presence of CD45+ immune cells (Figure 1B). The same
results were obtained using five independent PDEC isolates,
indicating that GFP-KrasG12D-PDEC implants possess an
intrinsic capacity to invoke a robust stromal response. Sham
injections had no apparent effect on the pancreatic parenchyma
(data not shown), ruling out the contribution of injury-induced
inflammation to the observed immune response. GFP-labeled
wild-type PDECs (GFP-WT-PDECs) failed to engraft (Figure S1A
available online) consistent with their previously reported survival
disadvantage relative to KrasG12D-PDEC (Lee and Bar-Sagi,
2010).
To ascertain whether the immunologic reaction evoked by
KrasG12D-PDECs in the orthogenic system is physiologically
relevant, we compared by flow cytometry analysis the overall
abundance and subtype distribution of immune cells in pan-
creata containing GFP-KrasG12D-PDEC grafts and pancreata
from p48-Cre;LSL-KrasG12D mice (Hingorani et al., 2003). At
8 weeks after implantation, the abundance of CD45+ cells inGFP-KrasG12D-PDEC pancreata was similar to that observed in
pancreata from 12-week-old p48-Cre;LSL-KrasG12D mice (Fig-
ure S1B), which, at this stage, typically display early PanIN
lesions that are scattered throughout the organ (Hingorani
et al., 2003). By and large, the distribution of the major immune
cell subtypes was similar in both models (Figure 1C). In addition,
both models displayed an increased intrapancreatic as well
as splenic accumulation of Gr1+CD11b+ myeloid cells and
CD4+Foxp3+CD25+ regulatory T cells (Tregs), compared with
normal pancreas and spleen (Figure 1D and Figures S1C and
S1D) and in agreement with the reported increase in the abun-
dance of these putative immunosuppressive cell populations
during early pancreatic neoplasia (Clark et al., 2007). Together,
these observations credential the use of KrasG12D-PDECs to
elucidate the interaction of the neoplastic epithelium with the
host immune system and suggest that oncogenic activation of
Kras may be sufficient to instigate immune responses that
contribute to disease progression.
To further test this idea, we sought to identify mechanisms
by which the expression of oncogenic Kras in PDECs could
modulate an immune reaction. Given the documented effect of
oncogenic forms of Ras on the expression of immune mediators
(Ancrile et al., 2008; Coppe´ et al., 2008), we began by analyzing
the supernatants of wild-type and GFP-KrasG12D-PDECs for
cytokine production using the Milliplex cytokine bead panel
(Figure 2A and Figure S2A). Of the 32 cytokines represented
in this panel, GM-CSF was most robustly upregulated in GFP-
KrasG12D-PDECs (Figure 2A and Figure S2A). The increase in
GM-CSF protein levels was corroborated by an increase in the
levels of GM-CSF transcripts, suggesting a role for KrasG12D in
the transcriptional upregulation ofGM-CSF (Figure 2A). Pharma-
cological inhibition of either PI-3K or MAPK pathways resulted in
abrogation of GM-CSF expression in GFP-KrasG12D-PDECs,
indicating that the regulation of GM-CSF expression by onco-
genic Kras is mediated by multiple effector pathways (Figure 2B
and Figure S2B).
To examine whether increased GM-CSF expression is also
a feature of pancreatic neoplasia in vivo, we first used ELISA
analysis of tissue supernatants to measure the production of
GM-CSF in GFP-KrasG12D-PDEC and p48-Cre;LSL-KrasG12D
pancreata in comparison to that from normal pancreatic
tissues. In both model systems, GM-CSF levels were found to
be significantly upregulated (Figure 2C). Next, we evaluated
the production of GM-CSF in human PDA by immunohisto-
chemical staining of tissue sections. At least 75% of all PanINs
within a section had to exhibit 50% or more GM-CSF-stained
cells per lesion to be considered positive. Using this criterion,
14 of the 16 PDA patient samples were positive for GM-CSF
staining of PanIN lesions (Figure 2D). Invasive PDA lesions
were also positive for GM-CSF expression, indicating that
GM-CSF upregulation persists through disease progression
(Figure 2D). Of note, compared to PDA-associated PanIN
lesions, pancreatic lesions from four non-PDA cases (chronic
pancreatitis, pancreatic dermoid cyst, pancreatic endocrine
neoplasm, and serous cystadenoma) had no detectable GM-
CSF expression (Figure S2C and data not shown). Because
these diseases typically are not associated with mutations
in the Kras allele, the absence of GM-CSF expression is con-
sistent with a role for oncogenic Kras signaling in GM-CSFCancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc. 837
Figure 1. Orthotopic Implantation of KrasG12D-PDECs Generates a Robust Immune Response
(A) Sections from orthotopic pancreatic grafts formed by GFP-KrasG12D-PDECs at 4 weeks after implantation were stained with hematoxylin and eosin (H&E;
scale bar, 500 mm; inset scale bar, 25 mm), anti-GFP antibody (scale bar, 50 mm), and Trichrome blue (scale bar, 100 mm).White arrowheads indicate GFP-positive
neoplastic pancreatic ducts; black asterisk indicates neoplastic ducts; Ac stands for acinar compartment.
(B) Immunofluorescence staining for CD45 and CK19 in pancreata of normal sham-injected control and orthotopic GFP-KrasG12D-PDEC animals (4 weeks after
implantation). CK19 was used to identify ductal epithelia, CD45 was used to identify immune cells, and nuclei were counterstained with DAPI. White asterisk
indicates pancreatic ductal structures (left panel) and grafted ductal structures (right panel); white arrowheads indicate CD45+ cells. Scale bar, 100 mm.
(C) Percentage of immune cell types in pancreata was determined by flow cytometry of pancreatic tissue and quantified. After gating on the CD45+ population,
cells were analyzed for the presence of respective lineage markers (percentage of each immune cell subtype out of total number of live cells sorted from the
pancreas is shown). Error bars indicate SD (n = 3–8 mice per group).
(D) Flow cytometry analysis of pancreatic tissue for the presence of Gr1+CD11b+ myeloid and Foxp3+CD25+ Tregs. After gating on the CD45+ population (top),
cells were analyzed for the presence of Gr1+CD11b+ subpopulation. The graph shows the percentage of Gr1+CD11b+ cells out of the total number of live cells
sorted from the pancreas. After gating on CD45+CD3+ T cells (bottom), cells were gated on CD4+ to examine intracellular Foxp3 versus surface CD25 staining.
The graph shows the percentage of Tregs out of the total number of CD4+ T cells. Representative flow cytometry plots are shown. Error bars indicate SD; INS,
insufficient number of cells for analysis (n = 4–8 mice per group).
*p < 0.05; **p < 0.01; NS, not significant. See also Figure S1.
Cancer Cell
KrasG12D Modulates Immunity in Pancreatic Cancerupregulation. Together, these results suggest that heightened
tumor cell-derived GM-CSF levels represent an early KrasG12D-
dependent facet of pancreatic neoplasia that is sustained over
the course of malignant transformation.838 Cancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc.GM-CSF plays a versatile role in the development of immuno-
logical responses and has been implicated in the regulation of
proliferation and maturation of multiple immune cell lineages,
including monocyte, granulocyte, dendritic cells, and putative
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Figure 2. GM-CSF Is Upregulated in KrasG12D-PDECs as Well as PanIN-Harboring Mouse and Human Pancreata
(A) Levels ofGM-CSFmRNA (black bar) and protein (gray bar) in GFP-KrasG12D-PDEC were assessed by quantitative RT-PCR and ELISA, respectively. Data are
presented as an average fold induction over values from isogenic GFP-WT-PDECs. Error bars indicate SD (n = 3).
(B) Normalized expression of GM-CSF mRNA in GFP-KrasG12D-PDECs (black bars) after 24 hr of treatment with DMSO, MAPK inhibitor U0126 (2 mM), or PI3K
inhibitor LY294002 (10 mM) was analyzed by quantitative RT-PCR. Error bars indicate SD (n = 3).
(C) Levels of GM-CSF protein in pancreata grafted withGFP-KrasG12D-PDECs or pancreata from p48;LSL-KrasG12Dmice. Data are presented as an average fold
induction over values from normal pancreatic tissue. Error bars indicate SD (n = 3).
(D) Immunohistochemical staining for GM-CSF protein in representative samples of human pancreatic cancer containing PanIN lesions (a, normal duct
from adjacent nonmalignant tissue; b and c, PanIN lesions; d, invasive PDA). White arrowheads indicate pancreatic duct (a), PanIN (b and c), and PDA (d). Scale
bar, 50 mm.
See also Figure S2.
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KrasG12D Modulates Immunity in Pancreatic Cancerimmunosuppressive Gr1+CD11b+ myeloid cells (Barreda et al.,
2004). Because Gr1+CD11b+ cell accumulation is consistently
observed in GFP-KrasG12D-PDEC and p48-Cre;LSL-KrasG12D
pancreata (Figure 1D), we sought to determine whether the
GM-CSF produced by GFP-KrasG12D-PDEC can induce the
differentiation of progenitor Gr1CD11b cells to Gr1+CD11b+.
As illustrated in Figure 3A, the coculturing of bone marrow-
derived LinnegCD34+ hematopoietic progenitor cells (HPCs)
with GFP-KrasG12D-PDECs that were seeded on Transwell
inserts, induced an accumulation of Gr1+CD11b+ cells. Re-
combinant GM-CSF alone was used as a positive control (Fig-
ure 3A). The addition of neutralizing anti-GM-CSF monoclonal
antibody MP1-22E9 (a-GM) (Scho¨n et al., 2000) significantly
attenuated the expansion of Gr1+CD11b+ cells, indicating
that their generation is largely dependent on GFP-KrasG12D-
PDEC-derived GM-CSF (Figure 3A). To establish whether these
Gr1+CD11b+ cells display suppressive activity, the coculture-
derived, sorted, double-positive population was incubated with
splenic T cells, and the CD3/CD28-induced proliferation of
CD3+ T cells was assessed by BrdU incorporation. Proliferation
of CD3+ cells was inhibited in the presence of Gr1+CD11b+ cells,
indicating that GM-CSF produced by KrasG12D-PDEC can drivethe generation of differentiated Gr1+CD11b+ myeloid cells
with immunosuppressive potential (Figure 3B). Significantly,
Gr1+CD11b+ double-positive cells but not Gr1CD11b+ single-
positive cells isolated from GFP-KrasG12D-PDEC grafted pan-
creata suppressed proliferation of splenic T cells (Figure 3C),
indicating that the accumulation of Gr1+CD11b+ cells at the sites
of pancreatic neoplasia could contribute to the induction of a
tolerogenic immune state. Because we have observed that the
numbers of Gr1+CD11b+ cells were augmented in the spleens
of orthotopically injected animals, we sought to determine
whether there was a systemic increase in the levels of GM-CSF
following engraftment of GFP-KrasG12D-PDECs. We found that
the levels of circulating GM-CSF in mice with GFP-KrasG12D-
PDEC lesions were significantly elevated as compared to control
animals (Figure 3D), suggesting that, in addition to its localized
intrapancreatic effect, GM-CSF production by KrasG12D-PDECs
may affect hematopoietic processes in secondary lymphoid
organs.
To establish whether the upregulation of GM-CSF in KrasG12D-
PDECs is responsible for the accumulation of Gr1+CD11b+
in vivo, we utilized short hairpin RNAi to stably knock down
GM-CSF expression in GFP-KrasG12D-PDECs. A significantCancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc. 839
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Figure 3. KrasG12D-PDECs Promote Accumulation of Immunosuppressive Gr1+CD11b+ Cells in a GM-CSF-Dependent Manner
(A) Flow cytometry analysis of LinnegCD34+ hematopoietic progenitor cells for the surface markers CD11b and Gr1 following coculture with GM-CSF or GFP-
KrasG12D-PDECs with or without a-GM-CSF antibody (a-GM). Representative flow cytometry plots and a graph indicating percentage of the Gr1+CD11b+ cells
out of the total number of live cells are shown. Error bars indicate SD (n = 3).
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KrasG12D Modulates Immunity in Pancreatic Cancerreduction of GM-CSF at the level of both mRNA and protein was
achieved using two independent hairpin sequences (Figure 3E).
GM-CSF knock-down did not produce an adverse effect on the
growth of GFP-KrasG12D-PDEC in culture (Figure 3F), consistent
with our findings that these cells do not express the GM-CSF
receptor beta chain CD131 (data not shown). We next analyzed
the composition of leukocytic infiltrates in pancreata grafted
with GFP-KrasG12D-PDECs expressing scrambled (scr-GFP-
KrasG12D-PDEC) or GM-CSF shRNAs (GM-sh1- and GM-sh2-
GFP-KrasG12D-PDEC). Among all CD45+ cells found in the
pancreas, GM-CSF knock-down led to a specific reduction in
the abundance of Gr1+CD11b+ cells but not Gr1CD11b+ cells
(Figures 3G and 3H), indicating that the production of GM-CSF
by ductal cells harboring the KrasG12D allele is necessary to
promote local accumulation of immune cells of the Gr1+CD11b+
lineage.
Because Gr1+CD11b+ myeloid cells have been implicated in
tumor-induced immune tolerance (Gabrilovich and Nagaraj,
2009), we reasoned that the KrasG12D-PDEC-mediated produc-
tion of GM-CSF and the resulting accumulation of Gr1+CD11b+
cells could be critical for the establishment of an immunosup-
pressive environment that is growth permissive. To investigate
this possibility, we have characterized the engraftment of GFP-
KrasG12D-PDEC in relation to GM-CSF production. As illustrated
in Figure 4A, the implantation frequency of GM-sh-GFP-
KrasG12D-PDECs was significantly reduced as compared to
scr-GFP-KrasG12D-PDECs, and the average size of the knock-
down lesions was significantly decreased. To gain insight into
the process underlying compromised engraftment of GM-sh-
GFP-KrasG12D-PDECs, we analyzed the fate of the grafts at
different time points after implantation by immunohistochemical
staining against GFP. At 1 week after implantation, grafts
generated from scr- and GM-sh-GFP-KrasG12D-PDECs were
essentially indistinguishable with respect to size, histological
appearance, and cell number (Figure 4B and Figure S3). Thus,
it appears that GM-CSF deficiency has no adverse effect on
the initial growth and survival capabilities of KrasG12D-PDEC
in vivo. However, at 2 weeks after implantation, although scr-
GFP-KrasG12D-PDEC grafts displayed a sizable expansion and
the characteristic elaboration of ductal structures, graft areas
in pancreata that were implanted with GM-sh-GFP-KrasG12D-
PDECs were virtually devoid of GFP-positive cells (Figure 4B
and Figure S3). These observations are consistent with the(B) Quantification of BrdU+CD3+ T cells treated as indicated. T cells and Gr1+CD
(C) Representative quantification of BrdU+CD3+ T cells cocultured with either Gr
injection withGFP-KrasG12D-PDECs. For proliferation assays, myeloid cells and T
aCD3-coated wells and in the presence of aCD28 serve as control. Error bars in
(D) Expression of mouse GM-CSF in the sera of either uninjected mice (control, n
was measured using ELISA. Each symbol represents a mouse, and mean values
(E) Relative expression ofGM-CSFmRNA (gray bars, left axis) and protein (black
containing either scrambled shRNA (scr) or GM-CSF shRNAs (GM-sh1, GM-sh2) w
(F) Growth analysis of scr (circles), GM-sh1 (squares), and GM-sh2 GFP-Kr
SD (n = 3).
(G) Representative flow cytometry plots of pancreatic immune cells for the surfac
GM-sh1-, and GM-sh2 GFP-KrasG12D-PDEC. After gating on the CD45+ populat
(H) Quantification of relative abundance of Gr1+CD11b+ and Gr1CD11b+ cell
Gr1CD11b+ cells (black bars) and double-positive Gr1+CD11b+ population (gray
per group).
**p < 0.01; ***p < 0.001; NS, not significant.postulate that the production of GM-CSF enables KrasG12D-
PDEC to engage host-dependent responses that favor their
maintenance and expansion.
Recent studies have indicated that Gr1+CD11b+ cells may
contribute to tumor immune evasion by restraining the activity
of CD8+ T cells (Gabrilovich and Nagaraj, 2009; Marigo et al.,
2008). To examine the relevance of this mechanism to the
engraftment potential of KrasG12D-PDECs, the accumulation of
CD8+ T cells was analyzed by immunohistochemistry. The
pancreatic parenchyma associated with grafts from scr-GFP-
KrasG12D-PDECs was devoid of CD8+ T cells both at 1 and
2 weeks after implantation (Figure 5A and Figure S4A). In
contrast, a pronounced accumulation of CD8+ T cells in the
parenchyma of GM-sh-GFP-KrasG12D-PDEC grafts was de-
tected at 2 weeks after implantation (Figure 5A). A similar pattern
of CD8+ cell accumulation was observed when control or
GM-sh-KrasG12D-PDEC lacking GFP expression were injected
into the pancreas, indicating that the CD8+ T cell response was
not instigated by ectopically expressed GFP, but was elicited
by the transformed epithelium (Figure S4B). Significantly no
infiltration of CD8+ cells was observed at 1 week after implanta-
tion in GM-sh-GFP-KrasG12D-PDEC grafts (Figure S4A), consis-
tent with the time requirement associated with the priming of
the adaptive immune responses. Of note, at later time points
after implantation (4 weeks), some of the CD8+ T cells were
found in clusters that contain B cells, likely signifying the for-
mation of secondary lymphoid tissue, which is indicative of a
persisting immune response (Carragher et al., 2008) (Figure 5B).
Coincident with the accumulation of CD8+ T cells, we have
observed an increase in the frequency of apoptosis within the
GM-CSF knock-down grafts only at 2 weeks after implantation
(Figure 5A and Figure S4A). These results suggest that, in the
absence of GM-CSF, the cytotoxic activity of CD8+ T cells at
the site of engraftment may be responsible for the clearance of
implanted GFP-KrasG12D-PDECs. A prediction borne by this
interpretation is that the growth defect of GM-sh KrasG12D-
PDECs would be rescued by CD8+ T cell depletion. To test this
prediction, we performed orthotopic implantations in animals
depleted of CD8+ T cells by intraperitoneal administration of
anti-CD8 antibody over a period of 2 weeks. This regiment
resulted in >90% depletion of CD3+CD8+ T cells (Figure S5). At
2 weeks after implantation, no GM-sh-GFP-KrasG12D-PDECs
were detected in pancreata animals injected with control11b+ cells were cocultured at a 1:1 ratio. Error bars indicate SD (n = 3).
1CD11b+ or Gr1+CD11b+ cells isolated from mouse pancreata 8 weeks after
cells were cultured at ratios of 1:1, 1:5, or 1:10 respectively. T cells incubated in
dicate SD (n = 3).
= 4) or mice with GFP-KrasG12D-PDEC grafts 8 weeks after implantation (n = 5)
for each group are represented by black lines.
bars, right axis) in GFP-KrasG12D-PDECs 4 days after infection with lentiviruses
as assessed by quantitative RT-PCR and ELISA. Error bars indicate SD (n = 3).
asG12D-PDEC (triangles) was assessed by MTT assay. Error bars indicate
e expression of Gr1 and CD11b markers at 4 weeks after implantation of scr-,
ion, cells were analyzed for the presence of CD11b+ and Gr1+ populations.
populations is presented as a percentage change in CD45+ single-positive
bars) relative to scr GFP-KrasG12D-PDECs. Error bars indicate SD (n = 6 mice
Cancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc. 841
AB
scr 2hs-MG1hs-MG
2keew1keew
2hs-MGrcs
* *
L
e
s
i
o
n
 
s
i
z
e
 
(
m
m
3
)
scr GM-sh1 GM-sh2
L
e
s
i
o
n
 
f
r
e
q
u
e
n
c
y
14
10
6
2
1.2
1.0
0.8
0.6
0.4
0.2
scr 2hs-MG1hs-MG
scr GM-sh2
α
G
F
P
frequency
size
Pancreas
Spleen
Colon
* *
*
*
Figure 4. Functional Consequence of Ablating GM-CSF on Growth of KrasG12D-PDECs In Vivo
(A) Gross anatomical view of scr- and GM-sh GFP-KrasG12D-PDEC grafts (top, dotted outlines and arrows) at 8 weeks after implantation. Scale bar, 5 mm.
Quantification of the graft size at 8 weeks after implantation (gray bars, left axis) and percentage of overall lesion frequency (black bars, right axis) is indicated in
the graph. Error bars indicate SD (n = 3). Sections from pancreata containing scr- and GM-shGFP-KrasG12D-PDEC orthotopic grafts at 4 weeks after implantation
were stained with H&E (bottom, lesions are delineated by dotted outlines). Scale bar, 500 mm.
(B) Immunohistochemical staining for GFP on sections of scr- and GM-sh GFP-KrasG12D-PDEC orthotopic grafts at 1 and 2 weeks after implantation. Red
asterisks indicate engrafted area. Scale bar, 100 mm.
*p < 0.05. See also Figure S3.
Cancer Cell
KrasG12D Modulates Immunity in Pancreatic Cancerantibody (Figure 6), and the implanted area displayed many
apoptotic cells (data not shown). In contrast, the injection of
anti-CD8 antibody was sufficient to permit the establishment of
GM-sh-GFP-KrasG12D-PDEC grafts that were indistinguishable
in size and overall appearance from scr-GFP-KrasG12D-PDEC
grafts (Figure 6), indicating that CD8+ T cells are the primary
immune cell type responsible for mounting and executing the
immune response against KrasG12D-PDEC.
DISCUSSION
The critical role of host immunity in regulating tumorigenesis is
undisputed (Grivennikov et al., 2010). Furthermore, it is
becoming increasingly evident that immune cells in the tumor
microenvironment fail to mount an effective antitumor immune
response (Ruffell et al., 2010). However, the underlying mecha-
nisms that allow tumors to escape immune surveillance have
not been fully characterized. In the present study, we implicate
oncogenic Kras in restraining the antitumor immune response842 Cancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc.through the production of GM-CSF and the subsequent
suppression of T cell immunity. This immune evasion strategy
may contribute to immunotherapeutic resistance in oncogenic
Kras-driven cancers.
The progression of pancreatic neoplasia is accompanied by
cellular and molecular alterations in both the parenchymal and
stromal compartments of the pancreas (Kleeff et al., 2007). The
parenchymal component gives rise to PanINs, and the con-
tribution of oncogenic Kras to this transition has been amply
documented using genetically engineered mouse models
(Hingorani et al., 2003, 2005). In contrast, little is known about
the stroma-modulating capabilities of oncogenic Kras during
the early stages of pancreatic cancer. The demonstration that
GM-CSF production in response to activation of Kras modulates
the immune reaction to pancreatic precursor lesions thus
provides insights into how this oncogenic event could lead to
the reprogramming of the microenvironment from the very
beginning of the disease. The recent demonstration of the role
of pancreas-specific oncogenic activation of Kras in generating
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Figure 5. Engraftment of GM-CSF Knock-Down KrasG12D-PDEC Is Accompanied by an Increase in Infiltrating CD8+ T Cells
(A) Immunohistochemical staining and quantification of CD8 and cleaved caspase 3 staining on sections of scr- and GM-sh GFP-KrasG12D-PDEC orthotopic
grafts at 2 weeks after implantation. CD8+ or cleaved caspase3-positive cells within the boundaries of orthotopic grafts were counted per field of view (FOV) at
203magnification. White arrowheads indicate CD8+ cells; black arrowheads indicate caspase-3-positive cells. Scale bars, 50 mm. Error bars indicate SD (n = 4
mice per group, 4 FOV per mouse).
(B) Immunohistochemical staining for CD8 and B220 on consecutive sections of scr- and GM-sh GFP-KrasG12D-PDEC orthotopic grafts at 4 weeks after
implantation. Numbers of CD8+ cells were counted per FOV at 203magnification and are shown in the graph. Arrows indicate coaggregation of CD8+ cells and
B220+ cells. Scale bar, 100 mm. Error bars indicate SD (n = 3 mice per group, 5 FOV per mouse).
***p < 0.001. See also Figure S4.
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KrasG12D Modulates Immunity in Pancreatic Cancera protumorigenic inflammatory microenvironment (Fukuda et al.,
2011; Lesina et al., 2011) further underscores the crucial con-
tribution of non-cell-autonomous mechanisms to pancreatic
tumor initiation and progression.
The identification of GM-CSF as a transcriptional target of
oncogenic Kras in PDECs is consistent with the existence of
Ras-regulated transcription factor-binding sites, such as AP-1
and ETS, in the GM-CSF promoter region (Osborne et al.,
1995). The pathophysiological relevance of the activation of
this transcriptional program is indicated by the increased levels
of GM-CSF we have observed in human PanIN lesions. It is
possible that a similar Kras-mediated mechanism of GM-CSF
upregulation is responsible for the enhanced serum levels of
GM-CSF detected in patients with pancreatic cancer (Mroczko
et al., 2005). Our initial analysis suggests that the upregulation
of GM-CSF in response to oncogenic Kras is mediated by the
concerted action of multiple effector pathways, including Erk
and PI-3K (Figure 2B). Because these pathways are frequently
activated in various malignancies, the induction of GM-CSFmight not be restricted to oncogenic Kras-driven cancers and/
or the pancreas. This idea is supported by studies demonstrating
the overexpression of GM-CSF in several human cancer lines,
including those of breast, bladder, and melanoma origin (Bronte
et al., 1999; Dolcetti et al., 2010; Steube et al., 1998). Thus, the
functional significance of GM-CSF upregulation might have
broader implications.
Under normal physiological conditions, GM-CSF serves as
a bona fide growth factor for hematopoietic cells, promoting
the proliferation and maturation of multiple myeloid cell lineages
in a concentration-dependent manner (Barreda et al., 2004). In
neoplastic settings, GM-CSF has been shown to be endowed
with the potential to exert both pro- and antitumorigenic effects
by suppressing or enhancing tumor immunity, respectively
(Hamilton, 2008). Our findings demonstrate that, in pancreatic
ductal cells harboring oncogenic Kras, GM-CSF production is
linked to the expansion of Gr1+CD11b+ myeloid cells. A similar
consequential relationship between GM-CSF generation and
Gr1+CD11b+ cell expansion has been documented in otherCancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc. 843
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Figure 6. CD8+ T Cells Are Instrumental in the Clearance of GM-CSF Knock-Down KrasG12D-PDECs
(A) Orthotopic grafts formed by scr- or GM-sh GFP-KrasG12D-PDECs implanted into either mock-depleted (IgG) or CD8-depleted animals were analyzed at
2 weeks after implantation by H&E. Black arrowheads indicate pancreatic ductal structures. Scale bar, 100 mm.
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implantation was analyzed by immunohistochemistry for GFP. Scale bar, 100 mm.
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5 FOV per mouse).
***p < 0.001; NS, not significant. See also Figure S5.
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KrasG12D Modulates Immunity in Pancreatic Cancertumor models (Dolcetti et al., 2010; Marigo et al., 2010; Morales
et al., 2010). However, in the mouse, Gr1+CD11b+ double-posi-
tive cells represent a heterogeneous population composed of
myeloid derived suppressor cells, monocytes, and immature
myeloid cells (Ostrand-Rosenberg and Sinha, 2009). Several
lines of evidence suggest that the Gr1+CD11b+ cells that
accumulate in response to GM-CSF production by pancreatic
precursor lesions are immunosuppressive in nature. First,
when isolated from pancreata grafted with GFP-KrasG12D-
PDECs, the Gr1+CD11b+ cells displayed a suppressive effect
in a T cell proliferation assay. Second, the reduction in the
abundance of Gr1+CD11b+ cells following the suppression of
GM-CSF expression in vivo was accompanied by the infiltration
of CD8+ T cells. Third, the immune response-mediated elimina-
tion of orthotopic GFP-KrasG12D-PDEC lesions observed under
these conditions could be fully rescued by CD8+ T cell depletion,
indicating a principal role for Gr1+CD11b+ cells in disrupting
T cell immune surveillance during the early stages of pancreatic
neoplasia. The potential relevance of this immune modulatory
mechanism to more advanced stages of pancreatic cancer is
suggested by the reciprocal relationship between CD8+ T and
Gr1+CD11b+ cell infiltrates observed in pancreatic tumors from
the p48-Cre;LSL-KrasG12D mice (Clark et al., 2007).
GM-CSF is not unique in its ability to promote the expansion
and tumor mobilization of Gr1+CD11b+ immunosuppressive
cells. For example, IL1-b, IL-6, and VEGF have been shown to
induce the accumulation of Gr1+CD11b+ myeloid cells and the
concomitant suppression of T cell immune response in a variety
of mouse tumor models (Bunt et al., 2007; Melani et al., 2003;844 Cancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc.Pilon-Thomas et al., 2011; Tu et al., 2008). Significantly, IL1-b,
IL-6, and VEGF are targets of oncogenic Ras signaling, and their
production by cancer cells harboring oncogenic Ras has been
implicated in various protumorigenic processes, such as
inflammation, angiogenesis, and metastasis (Ancrile et al.,
2008; Coppe´ et al., 2008; Kranenburg et al., 2004). Because
the expression of IL1-b, IL-6, and VEGF inGFP-KrasG12D-PDECs
is not elevated relative to the levels measured in wild-type
PDECs (Figure S2A) and the suppression of GM-CSF production
is accompanied by a decrease in Gr1+CD11b+ cells, we
conclude that the production of GM-CSF by the precursor
lesions formed by these cells is necessary and sufficient to
induce the observed increase in Gr1+CD11b+ cells and the
impaired response of CD8+ T cells. The molecular mechanisms
responsible for the selective upregulation of GM-CSF observed
in KrasG12D-PDECs remain to be defined. Differences in genetic
profile, cellular background, and levels of Ras expression
between the experimental system described in this study and
those used in other reports could be important contributors.
Moreover, our findings do not rule out the possibility that IL1-b,
IL-6, and VEGF as well as potentially other secreted factors
can participate in establishing an immunosuppressive environ-
ment in oncogenic Ras-driven cancers. The existence of
such redundancy in the mechanism by which oncogenic Ras
can invoke tumor-induced tolerance may serve to secure the
sustenance of this mechanism at various stages of tumor
development.
Our studies reinforce the role of intrinsic immune surveillance
in restraining tumor initiation and support the idea that the
Cancer Cell
KrasG12D Modulates Immunity in Pancreatic Cancerevolution of pancreatic neoplasia is critically dependent on the
subversion of T cell responses against antigens that are ex-
pressed by pancreatic tumor cells. Although the specific antigen
recognized by the CD8+ cells in our experimental system
remains to be identified, it is of relevance to note that a T cell
response against oncogenic Ras has been documented in
a significant proportion of patients with PDA (Gedde-Dahl
et al., 1994; Kubuschok et al., 2006; Linard et al., 2002; Weijzen
et al., 1999). Given the ubiquitous occurrence of oncogenic Kras
mutations in pancreatic adenocarcinomas, the disruption of
mechanisms that induce T cell tolerance might offer a broadly
applicable strategy for the targeting of immune escape in
pancreatic cancer.
EXPERIMENTAL PROCEDURES
Animal Models
The LSL-KrasG12D and p48-Cre strains have been described previously
(Jackson et al., 2001; Kawaguchi et al., 2002). C57BL/6 mice were obtained
from The Charles River Laboratories. For orthotopic implantation of PDECs,
mice were anesthetized using a ketamine/xylazine cocktail, and a small
(7 mm) left abdominal side incision was made. PDECs (1 3 106 cells/mouse)
were suspended in Matrigel (Becton Dickinson) diluted 1:1 with cold PBS (total
volume of 50 ml) and were injected into the tail region of the pancreas using
a 26-gauge needle. A successful injection was verified by the appearance of
a fluid bubble without intraperitoneal leakage. The abdominal wall was closed
with absorbable Vicryl RAPIDE sutures (Ethicon), and the skin was closed with
wound clips (Roboz). Mice were sacrificed at the indicated time points, and
grafts were measured and processed for histology or flow cytometry. All
animal care and procedures were approved by the Institutional Animal Care
and Use Committee at NYU School of Medicine.
Isolation, Culture, and Infection of PDECs
Isolation, culture, and adenoviral infection of PDECs were performed as
previously described (Agbunag et al., 2006; Lee and Bar-Sagi, 2010). Lentiviral
vectors containing shRNAs directed against the GM-CSF gene (GM-sh1 and
GM-sh2; clone ID TRCN0000054618 and TRCN0000054620) and control
scrambled shRNA (scr) were obtained from Open Biosystems (pLKO.1, TRC
Consortium). Lentiviral vector encoding GFP (pLVTHM-GFP) was a kind gift
from Dr. F. Giancotti. To generate lentiviral particles, HEK293T cells were
cotransfected with the vector, the packaging construct (pHR-CMV-dR8.2),
and the envelope plasmid (pCMV-VSVG). Viral stocks were collected for
2 days, filtered through a 0.45 mm filter, and concentrated using 100MWCO
Amicon Ultra centrifugal filters (Millipore). A multiplicity of infection of 15 was
used for lentiviral infection of WT- or KrasG12D-PDECs in the presence of
10 mg/ml Polybrene (Chemicon).
Immunoblot Analysis
Cells were lysed in 1% Triton-X buffer (50 mM HEPES [pH 7.4], 1% Triton
X-100, 150 mM NaCl, 10% glycerol, 1 mM EGTA, 1 mM EDTA, 25 mM NaF,
1 mM Na vanadate, 1 mM phenylmethanesulfonyl fluoride [PMSF] and pro-
tease inhibitors). The following primary antibodies were used: mouse anti-
HA (12CA5), mouse anti-vinculin (Sigma-Aldrich), rabbit anti-phospho-ERK
(Cell Signaling), mouse anti-ERK (Cell Signaling), rabbit anti-phospho-AKT
(S473, Cell Signaling), and rabbit anti-AKT (Cell Signaling). After incubation
with either the secondary IRDye Alexa Fluor 680 goat anti-mouse antibody
or 800 goat anti-rabbit antibody (Molecular Probes), the membranes were
visualized with the Odyssey Infrared Imaging System (Li-Cor).
Quantitative RT-PCR
Extraction and reverse transcription of total RNA from PDECs was performed
using RNeasy mini kit (QIAGEN) and QuantiTect reverse transcription kit
(QIAGEN), respectively. SYBR Green PCR Master Mix (USB) was used
for amplification, and the samples were run on the Stratagene Mx 3005P.
Expression levels were normalized by GAPDH.Human Pancreas Specimens
The use of human tissue was reviewed and approved by the Institutional
Review Board of NYU School of Medicine, and samples (provided by the
Tissue Acquisition and Biorepository Service) were obtained after informed
consent. Sections (5 mm) were cut from formalin-fixed paraffin-embedded
samples for the purpose of immunohistochemistry. A total of 16 pancreatic
adenocarcinoma, one chronic pancreatitis, one benign pancreatic cyst, one
serous cystadenoma, and one intraductal papillary mucinous neoplasm
samples were analyzed.
Histology and Immunohistochemistry
Mouse pancreata were fixed overnight in 10% formalin (Fisher) and were pro-
cessed for paraffin embedding. For histology, deparaffinized sections (6 mm)
were stained with Harris hematoxylin and eosin (both from Sigma-Aldrich)
followed by an alcohol dehydration series and mounting (Permount, Fisher).
Trichrome staining was performed at NYU School of Medicine Histopathology
Core Facility. For immunohistochemistry, deparaffinized sections (6 mm) were
rehydrated and quenched in 1% hydrogen peroxide/methanol for 15 min, and
antigen retrieval was performed in 10mM sodium citrate and 0.05% Tween-20
(pH 6.0) for 15 min in a microwave oven. Blocking was done in 10% serum, 1%
BSA, and 0.5% Tween-20 for 1 hr at room temperature, followed by incubation
with the primary antibodies diluted in 2% BSA overnight at 4C. The following
primary antibodies were used: rabbit anti-GFP (Cell Signaling), rabbit anti-
GM-CSF (Novus Biologicals), rat anti-CD8 (53-6.7, BD Biosciences), rabbit
anti-cleaved caspase-3 (Cell Signaling), and rat anti-B220 (BD Biosciences).
After incubating with secondary biotinylated antibodies and ABC solution
(both from Vector Laboratories), sections were developed with 3,30-diamino-
benzidine tetrahydrochloride (Sigma-Aldrich). After counterstaining with
Harris hematoxylin (Sigma), slides were subjected to an alcohol dehydration
series and mounted with Permount (Fisher). Slides were examined on a Nikon
Eclipse 80i microscope.
Immunofluorescence
Mouse pancreata were embedded in OCT compound (Tissue-Tek) by snap
freezing OCT-covered tissues in liquid nitrogen, and 8 mm sections were cut
on a Leica microtome. After fixing the sections in 4% paraformaldehyde for
10 min on ice and permeabilizing with 0.25% Triton X-100 for 10 min on ice,
sections were blocked with 10% serum, 2% BSA, and 0.1% Tween-20 for
1 hr at room temperature. Incubation with primary antibodies diluted in 2%
BSA and 0.5% Tween-20 was performed overnight at 4C. The following
antibodies were used: rat anti-CD45 (BD Biosciences) and rat anti-CK19
(Troma III, developed by R. Kemler, made available by Developmental Studies
Hybridoma Bank under the auspices of the NICHD). After incubating with
Alexa Fluor-labeled secondary antibodies (Invitrogen) diluted in 1% BSA for
1 hr at room temperature, sections were stained with DAPI and mounted using
polyvinyl alcohol mounting media with DABCO (Fluka). Slides were examined
on a Zeiss Axiovert 200M microscope.
Flow Cytometry
Cellular suspensions from the tissues were prepared as follows: spleens were
mechanically disrupted, suspended in 1% FBS and PBS, passed through
a 70 mm strainer, and treated with RBC lysis buffer (eBioscience). Pancreata
were minced using sterile razor blades and were incubated in 1.25 mg/ml
collagenase type IV and 0.1% soybean trypsin inhibitor (Sigma-Aldrich) in
RPMI for 15 min at 37C. Cells were suspended in 1% FBS and PBS, were
passed through a 70 mm strainer, and were treated with RBC lysis buffer.
Single-cell suspensions from spleens and pancreata were blocked with anti-
CD16/CD32 antibody (Fc Block, BD Biosciences) for 5 min on ice and were
labeled with the following antibodies: anti-CD45.2 (104), anti-CD3ε (500A2),
anti-CD4 (RM4-5), anti-CD8a (53-6.7), anti-CD45R/B220 (RA3-6B2), anti-
CD19 (1D3), anti-CD11b (M1/70), anti-Gr1 (RB6-8C5), and anti-CD25
(PC61.5) (all from BD Biosciences). Staining for intracellular Foxp3 was per-
formed using Mouse Regulatory T Cell Staining Kit (FJK-16, eBioscience).
Dead cells were excluded by staining with propidium iodine (Sigma-Aldrich).
Flow cytometry was performed on FACScan (BD Biosciences) at NYU School
of Medicine Flow Cytometry Core Facility, and data were analyzed using
FlowJo software.Cancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc. 845
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For cytokine analysis of PDEC cultures, cells were cultured in complete
medium at a concentration of 1 3 106 cells/ml for 24 hr before supernatant
harvest. For cytokine analysis of mouse pancreata, the tissues were har-
vested, weighed, minced with a sterile razor blade, and incubated in 500 ml
of complete media for 24 hr before supernatant collection. Analysis of the
cytokines was done with Milliplex Map Immunoassay (Millipore) and the
Luminex 200 system (Luminex) according to the manufacturer’s instructions.
Where indicated, mouse GM-CSF protein levels were determined by Mouse
GM-CSF Quantikine ELISA Kit (mean MDD = 1.8 pg/ml; R&D Systems). For
analysis of GM-CSF levels in mouse sera, blood samples were collected
retro-orbitally, and the samples were processed according to the manufac-
turer of the ELISA kit.
Culture of Sorted HPCs
Bone marrow cells were isolated from C57Bl/6 mice, and HPCs were sorted
using Mouse Hematopoietic Stem and Progenitor Cell Isolation Kit (BD
Biosciences), according to the manufacturer’s instructions. Isolated HPCs
were cultured in 6-well plates (1 3 105 cells/well) for a total of 6 days. On
day 0, either GM-CSF (10 ng/ml, Monoclonal Antibody Core Facility at
Memorial Sloan-Kettering Cancer Center) or a 24 mm Transwell insert with
a 0.4 mm pore size (Corning Life Sciences) containing KrasG12D-PDEC (2 3
105 cells/insert) were added to the HPCs. On day 3, fresh cytokine or inserts
with cells were added. Where indicated, HPC cultures were supplemented
with either control IgG2a antibody (1 mg/ml, eBioscience) or anti-GM-CSF
antibody (1 mg/ml MP1-22E9, eBioscience). For T cell proliferation assays,
Gr1+CD11b+ cells were sorted on day 6 of culture. Cellular purity was greater
than 90%.
Proliferation and Viability Assays
For in vitro T cell proliferation assays, splenic T cells suspended in complete
RPMI mediumwere added to 96-well plates precoated with anti-CD3 antibody
(BD Biosciences) at a density of 53 104 cells/well. Anti-CD28 antibody (37.51,
eBioscience) was added to T cells at a concentration of 1 mg/ml. Autologous
Gr1+CD11b+ cells derived from coculture of KrasG12D-PDEC and HPC were
irradiated and added in triplicates directly to T cells (5 3 104 Gr1+CD11b+
cells/well) 24 hr before adding BrdU reagent. Pancreas-associated myeloid
Gr1CD11b+ or Gr1+CD11b+ cells were sorted from KrasG12D-PDEC-grafted
pancreata at 8 weeks after implantation and were added in triplicates and at
indicated ratios directly to T cells 24 hr before adding BrdU reagent (Sigma-
Aldrich). T cells were labeled by adding BrdU to the culture medium at a final
concentration of 10 mM for 48 hr. Staining for BrdU was achieved using APC
BrdU Flow Kit (BD Biosciences). The percentage of BrdU-positive T cells
was determined by FACS analysis of CD3+BrdU+ cells.
For KrasG12D-PDEC growth assays, cells were seeded at a density of 2,000
cells/well in a 96-well plate. At indicated time points, cell culture medium was
aspirated, the wells were washed with RPMI (without phenol red, BioWhit-
taker), and 0.5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT; Sigma-Aldrich) was added for 2 hr at 37C. The reagent was
aspirated, and 100 ml of DMSO was added to each well for 20 min at room
temperature. Plates were read at an absorbance of 570 nmusing a VERSAmax
microplate reader (Molecular Devices). For the day 0 time point, cells were
treated with MTT reagent 2 hr after plating.
CD8 Depletion
Mice were depleted of CD8+ T cells via intraperitoneal injection of control rat
IgG antibody (eBioscience) or anti-CD8a antibody at a concentration of
0.2 mg/mouse (53-6.72, Monoclonal Antibody Core Facility at Memorial
Sloan-Kettering Cancer Center). Injections were administered every day for
3 days prior to orthotopic injection, and twice a week thereafter until the
experimental endpoint. The efficiency of CD8+ T cell depletion was assessed
by FACS of splenic tissues using anti-CD3 and anti-CD8 antibodies.
Statistical Analyses
Data are presented as means ± standard deviations (SD). Quantification of
GFP positivity was performed using ImageJ analysis. Data were analyzed by
the Microsoft Excel or GraphPad Prism built-in t test (unpaired, two-tailed),
and results were considered significant at p < 0.05.846 Cancer Cell 21, 836–847, June 12, 2012 ª2012 Elsevier Inc.SUPPLEMENTAL INFORMATION
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